- Home
- Publications
- Publication Search
- Publication Details
Title
Nucleoside-Lipid-Based Nanocarriers for Sorafenib Delivery
Authors
Keywords
Sorafenib, Solid lipid nanoparticles, Nucleolipids, Hepatocarcinoma, Breast carcinoma, Luminal B
Journal
Nanoscale Research Letters
Volume 13, Issue 1, Pages -
Publisher
Springer Nature
Online
2018-01-11
DOI
10.1186/s11671-017-2420-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Acidic pH-Triggered Drug-Eluting Nanocomposites for Magnetic Resonance Imaging-Monitored Intra-arterial Drug Delivery to Hepatocellular Carcinoma
- (2016) Wooram Park et al. ACS Applied Materials & Interfaces
- Solid Lipid Nanoparticles for Image-Guided Therapy of Atherosclerosis
- (2016) Khalid Oumzil et al. BIOCONJUGATE CHEMISTRY
- Intracellular interactions of electrostatically mediated layer-by-layer assembled polyelectrolytes based sorafenib nanoparticles in oral cancer cells
- (2016) Radhika Poojari et al. COLLOIDS AND SURFACES B-BIOINTERFACES
- Multilayer-Coated Liquid Crystalline Nanoparticles for Effective Sorafenib Delivery to Hepatocellular Carcinoma
- (2015) Raj Kumar Thapa et al. ACS Applied Materials & Interfaces
- Cyclodextrin-Modified Porous Silicon Nanoparticles for Efficient Sustained Drug Delivery and Proliferation Inhibition of Breast Cancer Cells
- (2015) Alexandra Correia et al. ACS Applied Materials & Interfaces
- Sorafenib Treatment of Advanced Renal Cell Carcinoma Patients in Daily Practice: The Large International PREDICT Study
- (2015) D. Jäger et al. Clinical Genitourinary Cancer
- Lipid nanocarriers containing sorafenib inhibit colonies formation in human hepatocarcinoma cells
- (2015) Maria Luisa Bondì et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- Codelivery of Sorafenib and Curcumin by Directed Self-Assembled Nanoparticles Enhances Therapeutic Effect on Hepatocellular Carcinoma
- (2015) Haiqiang Cao et al. MOLECULAR PHARMACEUTICS
- Transferrin targeted core-shell nanomedicine for combinatorial delivery of doxorubicin and sorafenib against hepatocellular carcinoma
- (2014) Giridharan Loghanathan Malarvizhi et al. Nanomedicine-Nanotechnology Biology and Medicine
- Quantum Dot Lipid Oligonucleotide Bioconjugates: Toward a New Anti-MicroRNA Nanoplatform
- (2013) Ahissan Aimé et al. BIOCONJUGATE CHEMISTRY
- Efficient delivery of therapeutic small nucleic acids to prostate cancer cells using ketal nucleoside lipid nanoparticles
- (2013) Delphine Luvino et al. JOURNAL OF CONTROLLED RELEASE
- Preparation, in vitro release, and pharmacokinetics in rabbits of lyophilized injection of sorafenib solid lipid nanoparticles
- (2012) Hong Zhang et al. International Journal of Nanomedicine
- Antitumor activity of sorafenib-incorporated nanoparticles of dextran/poly(dl-lactide-co-glycolide) block copolymer
- (2012) Do Kim et al. Nanoscale Research Letters
- Nucleoside–Lipid-Based Nanoparticles for Cisplatin Delivery
- (2011) Salim Khiati et al. ACS Nano
- Bioavailability and pharmacokinetics of sorafenib suspension, nanoparticles and nanomatrix for oral administration to rat
- (2011) Xue-qing Wang et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- Anionic Nucleotide−Lipids forIn VitroDNA Transfection
- (2009) Salim Khiati et al. BIOCONJUGATE CHEMISTRY
- Nucleoside-based lipids at work: From supramolecular assemblies to biological applications
- (2008) Philippe Barthélemy COMPTES RENDUS CHIMIE
- Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling
- (2008) Scott M. Wilhelm et al. MOLECULAR CANCER THERAPEUTICS
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More